Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Zilbrysq

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

Cladribine capsules could become the first ever oral treatment for gMG

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

Johnson & Johnson’s Imaavy granted FDA approval for rare autoimmune disease gMG

Myasthenia gravis affects an estimated 700,000 people worldwide

- PMLiVE

Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

Regulatory submissions are expected to be complete in the first half of this year

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE

Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis

The company said it is planning to file for US approval of the drug in this indication

- PMLiVE

J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis

The severity of the rare autoimmune disease is heightened in paediatric patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links